Multiple myeloma is a type ofcancerof the plasma cells (a type of white blood cells) of the bone marrow. Plasma cells are protein-making cells that normally produce the different kinds of antibodies of the disease-fighting immune system. In multiple myeloma, the plasma cells undergo a malignan...
Multiple myeloma, malignant proliferation of cells within the bone marrow that usually occurs during middle age or later and increases in occurrence with age. Myelomas are slightly more common in males than in females and can affect any of the marrow-con
Myeloma is an accumulation of malfunctioning or "cancerous" plasma cells (plasma cell neoplasms, or a bone marrow dyscrasia). Canceris a group of disorders characterized by transformation of normal cells to abnormal cells that grow and multiply uncontrollably. The net effect is the appearance of ...
thevertebral bodies. As further bone is destroyed, calcium is released, resulting inhypercalcemia.Acute kidney insufficiencyis present in approximately 20% of patients with myeloma. Treatment can include chemotherapy, radiation therapy, andstem cell transplantation.55The 5-year survival rate is ...
Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report ...
Adjunctive anti-bone resorption therapy has become an important part of multiple myeloma (MM) treatment. Currently, no definite evidence exists that this therapy increases survival. We examined a cohort of 13 of 167 patients (8%) treated with the M-2 protocol who received adjuvant gallium nitrate...
We describe the surgical treatment, outcome and long-term survival of patients with multiple myeloma (MM) in response to conventional (CC) or high-dose (HDT) chemotherapy.Eighty-four patients diagnosed with MM were recruited for the study (51 male, 33 female; median age 62 years) and consecu...
Multiple myeloma (MM) is a plasma-cell malignancy that, in the United States, constitutes 1.1% of all malignancies, 13.8% of haematological malignancies and approx 2% of cancer deaths. The 5, 10 and 20-year survival rate for MM are 31, 10 and 4%, respectively. Potential complications of ...
the complex cross-talk between myeloma cells and surrounding non-cancer cells results in the successful growth of malignant subclones, with impacts on clonal revolution and resistance to therapies. MM: multiple myeloma; MMSCs: multiple myeloma stem cells; TME: tumor microenvironment; BM: bone ...
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108(13):3992–6. Article CAS Google Scholar Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014;7:33–42. ...